Brief: Newbury Pharmaceuticals Q1 Net Revenue SEK 11,185
Jan 10 (Reuters) - Newbury Pharmaceuticals AB
NEWBRY.ST :
* SEPTEMBER 2023 - NOVEMBER 2023 NET REVENUE WAS 11 185
(258) TKR.
* SEPTEMBER 2023 - NOVEMBER 2023 EBITDA WAS -2 734 (-5 442)
TKR.
Source text for Eikon: ID:nMFN5QXMGQ
Further company coverage: NEWBRY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Newbury Pharmaceuticals AB
See all newsBrief: Newbury Secures Hospital Portfolio Rights In Iraq
Brief: Newbury Signs Licence And Supply Deal For Guanfacine
Brief: Newbury Pharmaceuticals Gets Approval for Tofacitinib Newbury
Brief: Newbury Pharmaceuticals Secures Generic Approval For Dalbavancin Newbury
Brief: Newbury Pharmaceuticals Reports Q3 EBITDA Of SEK -4 Mln